- Home
- ALLE vs PEN Comparison
ALLE vs PEN Comparison
Compare ALLE & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLE | PEN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 12.6B |
| IPO Year | 2013 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ALLE | PEN |
|---|---|---|
| Price | $185.65 | $319.57 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 17 |
| Target Price | $193.64 | ★ $362.54 |
| AVG Volume (30 Days) | ★ 1.2M | 407.8K |
| Earning Date | 10-22-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.18% | N/A |
| EPS Growth | 9.09 | ★ 1155.56 |
| EPS | ★ 6.33 | 2.77 |
| Revenue | N/A | ★ $1,403,665,000.00 |
| Revenue This Year | $10.11 | $14.38 |
| Revenue Next Year | $5.97 | $12.44 |
| P/E Ratio | ★ $30.44 | $116.41 |
| Revenue Growth | N/A | ★ 17.50 |
| 52 Week Low | $125.00 | $262.94 |
| 52 Week High | $194.93 | $362.41 |
Technical Indicators
Market Signals| Indicator | ALLE | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 68.28 | 47.17 |
| Support Level | $139.29 | $315.83 |
| Resistance Level | N/A | $320.84 |
| Average True Range (ATR) | 4.76 | 2.56 |
| MACD | 1.27 | -0.29 |
| Stochastic Oscillator | 77.15 | 36.89 |
Price Performance
Historical ComparisonAbout ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.